Mesoblast Q1 Revenue Jumps 44% on Ryoncil Sales; MESO Surges 19% After Hours

Mesoblast Ltd. (MESO) reported a 44% increase in fiscal first-quarter net revenue for the period ended September 30, driven by strong sales of its Ryoncil therapy. The stock rose 19.49% to $16.00 in overnight trading after closing Tuesday at $13.39, up 1.59%. Ryoncil (remestemcel-L-rknd) net revenue reached $28 million, up from $19 million a year earlier. The drug, indicated for steroid-refractory acute graft-versus-host disease in pediatric patients, is the first FDA-approved mesenchymal stromal cell therapy. Operational highlights included completion of patient treatment in the Phase 3 MSB-DR004 trial of rexlemestrocel-L for chronic low back pain and a positive FDA meeting on a planned BLA filing for the therapy to prevent GI bleeding in end-stage heart failure patients with an LVAD. Mesoblast reported $99 million in cash as of 2026. "Our first-quarter results show continued momentum for Ryoncil sales," said CEO Dr. Silviu Itescu. MESO has traded between $11.89 and $21.50 over the past 52 weeks.